HomeAI · summaries
Storia in 2 fonti
The mysterious case of Eli Lilly's obesity drug
Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? And why are drugmakers spending so much on acquisitions? Find out on this week's "Readout LOUD."
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?
Exclusive: STAT has learned that Eli Lilly and the FDA allowed a 79-year-old to gain extraordinary access to an experimental obesity drug through the agency’s “compassionate use”…
- ·
Lilly's retatrutide has been offered to a single person via 'compassionate use' program
The "triple-G" weight loss drug, Pfizer's lung cancer trial results, and more biotech news from The Readout
- ·
At BIO, a glimpse behind Lilly and Chai’s partnership
RIP Sangamo, onshoring with drug manufacturing, and more biotech news from The Readout
- ·
fiercepharma.com
Lilly exec says MFN will affect company's obesity pill launch strategy in Europe: report
Eli Lilly plans to launch its oral obesity treatment Foundayo in Europe by the end of this year or early 2027, focusing on the direct-to-consumer market, Eli Lilly International…
- ·
Democrats press White House on who got special access to Eli Lilly’s new obesity drug
The unusual access to an experimental drug has captured the attention of the American public as well.
- ·
The mysterious case of Eli Lilly's obesity drug
Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? And why are drugmakers spending so much on acquisitions? Find out on this week's "Readout LOUD."
- ·
Supreme Court rules in weedkiller cancer case
Dems want to unmask Eli Lilly's obesity drug user, a new genome-editing tool raises ethics questions, and more health news